Current Report Filing (8-k)
August 02 2021 - 7:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
August 2, 2021
_____________________
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
26 Main Street, Suite 101, Chatham, New Jersey 07928
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area
code: (862) 904-8182
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
TNXP
|
The NASDAQ Global Market
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
Tonix Pharmaceuticals Holding Corp. (the “Company”)
updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences,
and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed
as Exhibits 99.01 and 99.02 hereto and incorporated herein by reference.
On August 2, 2021, the Company announced that it will hold a groundbreaking ceremony at its planned 45,000 square
foot clinical-scale manufacturing facility in the New Bedford Business Park in Massachusetts on August 3, 2021.
A copy of the press release is furnished as Exhibit 99.03 hereto and incorporated herein by reference.
The information in this Item 7.01 of this Current
Report on Form 8-K, including Exhibits 99.01, 99.02 and 99.03 attached hereto, shall not be deemed “filed” for
purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject
to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities
Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On August 2, 2021, the Company announced that it will
hold a groundbreaking ceremony at its planned 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park
in Massachusetts on August 3, 2021. The new facility is expected to house the Company’s Advanced Development Center (“ADC”)
for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious
diseases, including COVID-19. Plans for the ADC include single-use bioreactors and purification suites with equipment for Good Manufacturing
Practice (GMP) production of vaccines for clinical trials, including when fully operational, the capability of producing sterile vaccines
in glass bottles. The ADC is intended to be Biosafety Level 2 (BSL-2). At full capacity, the facility can employ up to 70 researchers,
scientists, manufacturing and technical support staff.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
|
Exhibit
No.
|
|
Description.
|
|
|
99.01
99.02
99.03
|
|
Corporate Presentation by the Company for August 2021
Abbreviated Corporate Presentation by the Company
for August 2021
Press release of the Company, dated August 2, 2021
|
SIGNATURE
Pursuant to the requirement of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
TONIX PHARMACEUTICALS HOLDING CORP.
Date: August 2, 2021
|
By: /s/ Bradley Saenger
|
|
Bradley Saenger
|
|
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024